GR3033482T3 - Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions. - Google Patents

Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions.

Info

Publication number: GR3033482T3
Authority: GR; Greece
Prior art keywords: endonexin; hepatitis; polypeptides; diagnostic; derived
Prior art date: 1992-07-08

Application number

GR20000401179T

Other languages

English (en)

Inventor

Sing-Hiem Yap

Original Assignee

Innogenetics Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-08

Filing date

2000-05-24

Publication date

2000-09-29

2000-05-24 Application filed by Innogenetics Nv filed Critical Innogenetics Nv

2000-09-29 Publication of GR3033482T3 publication Critical patent/GR3033482T3/el

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Animal Behavior & Ethology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Communicable Diseases (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Marine Sciences & Fisheries (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

GR20000401179T 1992-07-08 2000-05-24 Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions. GR3033482T3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP92401971		1992-07-08
EP93915810A EP0672136B1 (en)	1992-07-08	1993-07-06	Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions
PCT/EP1993/001745 WO1994001554A1 (en)	1992-07-08	1993-07-06	Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
GR3033482T3 true GR3033482T3 (en)	2000-09-29

Family

ID=8211682

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GR20000401179T GR3033482T3 (en)	1992-07-08	2000-05-24	Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions.

Country Status (12)

Country	Link
EP (2)	EP0968648A1 (el)
JP (2)	JPH07509776A (el)
AT (1)	ATE190351T1 (el)
AU (1)	AU676483B2 (el)
CA (1)	CA2139735A1 (el)
DE (1)	DE69328035T2 (el)
DK (1)	DK0672136T3 (el)
ES (1)	ES2146231T3 (el)
GR (1)	GR3033482T3 (el)
PT (1)	PT672136E (el)
SG (1)	SG46493A1 (el)
WO (1)	WO1994001554A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0741144B1 (en) *	1994-11-11	2002-07-24	Noboru Kaneko	Antiannexin-v monoclonal antibody, process for producing the same, and use therof
JP2001508054A (ja) *	1996-12-30	2001-06-19	イノジェネティックス・ナムローゼ・フェンノートシャップ	ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用
CA2305715A1 (en) *	1997-11-06	1999-05-20	Innogenetics N.V.	Host derived proteins binding hcv: medical, diagnostic and purification use
US6344362B1 (en)	1998-03-12	2002-02-05	Ministero Dell Universita'e Della Ricerca Scientifica E Tecnologica (M.U.R.S.T. )	Use of a recombinant protein as receptor of a hepatitis virus
IT1299581B1 (it) *	1998-03-12	2000-03-16	Ministero Dell Uni Della Ricer	Uso di una proteina ricombinante come recettore di un virus dell'epatite
JP2002525289A (ja) *	1998-09-01	2002-08-13	イノジェネティックス・ナムローゼ・フェンノートシャップ	アネキシンに結合するベンゾジアゼピンおよびベンゾチアゼピン誘導体ならびにｈｓｂｓａｇペプチド、それらの組成物ならびに使用
US7645739B2 (en)	2001-02-21	2010-01-12	Alavita Pharmaceuticals, Inc.	Modified annexin compositions and methods of using same
US7635680B2 (en)	2001-02-21	2009-12-22	Alavita Pharmaceuticals, Inc.	Attenuation of reperfusion injury
US7635676B2 (en)	2001-02-21	2009-12-22	Alavita Pharmaccuticals, Inc.	Modified annexin proteins and methods for their use in organ transplantation
US6962903B2 (en)	2001-02-21	2005-11-08	Alavita, Inc.	Modified annexin proteins and methods for preventing thrombosis
US20060057591A1 (en) *	2004-09-15	2006-03-16	Canadian Blood Services	Method for preventing viral infection
PL1858916T4 (pl)	2005-03-15	2015-04-30	Fujirebio Europe N V	Warianty wirusa zapalenia wątroby typu b z obniżoną wrażliwością na analogi nukleozydów i ich zastosowanie
TWI503413B (zh) *	2009-12-04	2015-10-11	Academia Sinica	用於ｂ型肝炎病毒相關疾病之非人類動物疾病模式
WO2014072526A1 (en) *	2012-11-12	2014-05-15	Ruprecht-Karls-Universität Heidelberg	Development of hbv- and/or hdv-susceptible cells, cell lines and non-human animals

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI861417A0 (fi) *	1985-04-15	1986-04-01	Endotronics Inc	Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
PT87083B (pt) *	1987-03-28	1992-07-31	Boehringer Ingelheim Int	Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
EP0288198A3 (en) *	1987-04-20	1989-03-29	Takeda Chemical Industries, Ltd.	Production of peptide
US4873316A (en) *	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE3737239A1 (de) *	1987-11-03	1989-10-12	Behringwerke Ag	Gentechnische herstellung von anticoagulatorischem protein pp4
EP0339285A3 (en) *	1988-03-31	1989-11-29	RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation)	Recombinant endonexin ii
FR2637184A1 (fr) *	1988-10-05	1990-04-06	Inst Nat Sante Rech Med	Anticorps monoclonal reconnaissant une region pre-s1 de la grande proteine d'enveloppe du virus de l'hepatite b et ses applications, notamment pour le diagnostic in vitro et le traitement de l'hepatite b
EP0389983A3 (en) *	1989-03-31	1991-01-16	Abbott Laboratories	Monoclonal antibodies to pres2 and pres1 polypeptides of the hepatitis b viral envelope
DE4012341A1 (de) *	1990-04-18	1991-10-24	Behringwerke Ag	Monoklonale antikoerper gegen pp4, verfahren zu ihrer herstellung und ihre verwendung

1993
- 1993-07-06 CA CA002139735A patent/CA2139735A1/en not_active Abandoned
- 1993-07-06 AT AT93915810T patent/ATE190351T1/de not_active IP Right Cessation
- 1993-07-06 EP EP99113609A patent/EP0968648A1/en not_active Withdrawn
- 1993-07-06 AU AU45646/93A patent/AU676483B2/en not_active Ceased
- 1993-07-06 WO PCT/EP1993/001745 patent/WO1994001554A1/en not_active Ceased
- 1993-07-06 ES ES93915810T patent/ES2146231T3/es not_active Expired - Lifetime
- 1993-07-06 EP EP93915810A patent/EP0672136B1/en not_active Expired - Lifetime
- 1993-07-06 JP JP6502941A patent/JPH07509776A/ja active Pending
- 1993-07-06 SG SG1996005112A patent/SG46493A1/en unknown
- 1993-07-06 DE DE69328035T patent/DE69328035T2/de not_active Expired - Fee Related
- 1993-07-06 PT PT93915810T patent/PT672136E/pt unknown
- 1993-07-06 DK DK93915810T patent/DK0672136T3/da active
2000
- 2000-05-24 GR GR20000401179T patent/GR3033482T3/el not_active IP Right Cessation
2002
- 2002-07-29 JP JP2002219651A patent/JP2003189759A/ja not_active Ceased

Also Published As

Publication number	Publication date
ES2146231T3 (es)	2000-08-01
JP2003189759A (ja)	2003-07-08
AU4564693A (en)	1994-01-31
DE69328035T2 (de)	2000-11-02
PT672136E (pt)	2000-08-31
JPH07509776A (ja)	1995-10-26
EP0968648A1 (en)	2000-01-05
ATE190351T1 (de)	2000-03-15
DK0672136T3 (da)	2000-08-21
WO1994001554A1 (en)	1994-01-20
AU676483B2 (en)	1997-03-13
EP0672136A1 (en)	1995-09-20
EP0672136B1 (en)	2000-03-08
SG46493A1 (en)	1998-02-20
DE69328035D1 (de)	2000-04-13
CA2139735A1 (en)	1994-01-20

Legal Events

Date	Code	Title	Description
2004-02-05	ML	Lapse due to non-payment of fees

Publication	Publication Date	Title
GR3033482T3 (en)	2000-09-29	Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions.
DK0591914T3 (da)	1999-08-16	Retrovirus fra HIV-gruppen og dets anvendelse
PT725824E (pt)	2003-08-29	Epitopos de celulas t humanas imunodominantes do virus da hepatite c
PT88222A (pt)	1989-06-30	Vorrichtung zur applikation vom implantaten
ATE140969T1 (de)	1996-08-15	Il-3 mit zusätzlichen cysteinresten und chemische modifikationen davon
NO952744D0 (no)	1995-07-11	Cytokinbegrensende midler
KR950700333A (ko)	1995-01-16	개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
DE69532996D1 (de)	2004-06-09	Peptidanaloge des menschlichen basischen myelinproteins
IT8223795A0 (it)	1982-10-18	Gamma), relativi veicoli di polipeptidi contenenti la sequenza espressione, loro procedimento di degli amminoacidi dell'interferone preparazione, composizioni umano immune (interferone umano farmaceutiche contenenti tali polipeptidi.
AU2445888A (en)	1989-05-04	Recombinant fowlpox virus, vectors for the expression of heterologous proteins and vaccines for poultry derived from this virus
IL101780A0 (en)	1992-12-30	Recombinant avipox virus,the culture of cells infected with this virus and vaccines for poultry derived from this virus
IT8619055A0 (it)	1986-01-10	Composizioni farmaceutiche comprendenti peptidi del gruppo colecistochinina-cerulina per il trattamento terapeutico degli statidi shock e dell'insufficienza respiratoria e cardiocircolatoria.
EP0712926A3 (el)	1996-07-03
ATE67783T1 (de)	1991-10-15	Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
ES2080060T3 (es)	1996-02-01	Proteinas que tienen actividad de union a interferon-gamma.
IL90975A0 (en)	1990-02-09	Non-glycosylated,recombining human il 2 in reduced form,the process for obtaining it and its use as a medicament
ATE310828T1 (de)	2005-12-15	Implantat und vektor zur behandlung von erworbenen krankheiten
DE68912478D1 (de)	1994-03-03	Rekombinantes Marek-Krankheitsvirus, Verfahren zu seiner Herstellung, und Vakzine.
DK0588177T3 (da)	2000-05-08	Interferon-alpha/beta-bindende protein, fremstilling heraf samt farmaceutiske præparater indeholdende proteinet
DE69116552D1 (de)	1996-02-29	Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen-herausforderungen
Centers for Disease Control (CDC	1992	Anonymous survey for simian immunodeficiency virus (SIV) seropositivity in SIV-laboratory researchers--United States, 1992
ATE103979T1 (de)	1994-04-15	Menschliches lymphotoxin.
Centers for Disease Control and Prevention (CDC	1998	Availability of new rabies vaccine for human use
Will et al.	1983	Hepatitis B after infection of a chimpanzee with cloned HBV DNA
FR2655855B1 (fr)	1992-04-10	Protection genetique d'animaux contre l'infection par le virus leucemogene bovin, et provirus et virus recombinant derive de ce virus.